Sign in

Sri Krishna (Krish)

@tellkrish.bsky.social
1.5K followers 136 following 22 posts

Stadtman Investigator @ Surgery Branch, NCI | Immunology & Cancer, T Cells & Mutations | Views don't represent NIH, HHS or US GOV |🇮🇳🇺🇸| Lab: ccr.cancer.gov/staff-directory/sri-…

PostsRepliesMedia
Sri Krishna (Krish) @tellkrish.bsky.social · 08/09/2025
A huge loss to science. www.nytimes.com/2025/09/07/s...
nytimes.com
David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87
021
Sri Krishna (Krish) @tellkrish.bsky.social · 16/12/2024
Very cool study
051
Sri Krishna (Krish) @tellkrish.bsky.social · 26/11/2024
Absolutely! It’s one of our major areas of interest including my labs :) the impetus is now on TIL in this space more than TCR tbh
120
Sri Krishna (Krish) @tellkrish.bsky.social · 25/11/2024
Can’t speak for Iovance - I’m sure they gave multiple trials ongoing since the success of native TIL in melanoma- but in our branch we’re very much still working on old school expansion of native TIL (targeting neoag) in solid epithelial cancers.
130
Sri Krishna (Krish) @tellkrish.bsky.social · 24/11/2024
The important conclusion is that bespoke TCR-T targeting private neoantigens CAN work (there was a prior study from PACT Biopharma with no responses). The goal is now to make this short term responses more durable. Lots of work ahead 3/3.
120
Sri Krishna (Krish) @tellkrish.bsky.social · 24/11/2024
Several interesting correlates show up - most of the responses were in patients who have not received TIL targeting the same mutation, and targeting CD8 neoantigens. They were nevertheless not durable (unlike TIL in melanoma) 2/3
010
Sri Krishna (Krish) @tellkrish.bsky.social · 24/11/2024
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky www.nature.com/articles/s41...
nature.com
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - Nature Medicine
Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...
44513
Sri Krishna (Krish) @tellkrish.bsky.social · 23/11/2024
If it had an alternative initiation mutation even a driver p53 mutation is dispensable. we’ve seen a patient tumor responded to mutp53 T cells but then progressed with a wt p53 tumor (both tumors : initial and prog, had KRAS mut which is likely the driver) pretty mind boggling how much we don’t know
120
Sri Krishna (Krish) @tellkrish.bsky.social · 23/11/2024
GoF p53 mutations have been prevalent in the field but there’s a recent study that has challenged this notion - might be of interest: aacrjournals.org/cancerdiscov...
aacrjournals.org
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Evaluation of a large panel of human cancer cells revealed that gain-of-function effects of mutant TP53 are not required for tumor growth and therapy resistance, whereas loss of wild-type TP53 functio...
110
Sri Krishna (Krish) @tellkrish.bsky.social · 18/11/2024
Thank you !
010
Sri Krishna (Krish) @tellkrish.bsky.social · 18/11/2024
Hello Jon - pls add me to this list thank you !
110
Sri Krishna (Krish) @tellkrish.bsky.social · 16/11/2024
Reposting this now that there’s more crowd here - it was lonely a year back 🧪🦠
0216
Sri Krishna (Krish) @tellkrish.bsky.social · 12/11/2024
Hello can I pls be added - figuring this out- thank you so much.
110
Sri Krishna (Krish) @tellkrish.bsky.social · 02/12/2023
🩺🦠🧪🔬 #Immunosky #Scisky
010
Sri Krishna (Krish) @tellkrish.bsky.social · 02/12/2023
We report that anti tumor T cells in the blood are very low in frequency, but are apparently less dysfunctional, more stem-like relative to the SAME T cell clones within the tumor. We were able to develop a gene signature of blood derived T cells and predict TCRs from the blood of patients.
000
Sri Krishna (Krish) @tellkrish.bsky.social · 02/12/2023
Can we find antitumor, neoantigenT cells and predict their TCRs in the blood of patients with metastatic solid tumors? How do their phenotypes compare to those within patient's tumor? We addressed these questions in our new Cancer_Cell study.
sciencedirect.com
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic c...
Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source for antitumor T cells. By single-cell transcriptomic profili…
2102
Sri Krishna (Krish) @tellkrish.bsky.social · 26/10/2023
Thank you for the kind words 🙏🏽
110
Sri Krishna (Krish) @tellkrish.bsky.social · 24/10/2023
Another day, another award for our branch chief Steve Rosenberg. This time, the Presidential National Medal of technology and innovation, for pioneering immunotherapy against cancer. 🧪🔬🦠🩺 #ImmunoSky www.cancer.gov/news-events/...
030
Sri Krishna (Krish) @tellkrish.bsky.social · 29/09/2023
As probably one of the few NIH researchers on here, I feel obligated to note that a US federal govt shutdown will also impact the approx 1500 clinical trials being conducted at the NIH, including those against cancer, Alzheimer's, and many other diseases. Hopefully it is averted. 🩺🦠🔬🧪
4266127
Sri Krishna (Krish) @tellkrish.bsky.social · 19/09/2023
🧪🔬🦠🩺Pls share. We are evaluating postdoc candidates with interests computational or experimental immunology, or tumor biology, immunotherapy, T cell immunology, or genome engineering. ccr.cancer.gov/careers/post...
035
Sri Krishna (Krish) @tellkrish.bsky.social · 13/09/2023
Here is the direct link to the postdoc positions: pls contact if interested here and elsewhere. ccr.cancer.gov/careers/post...
000
Sri Krishna (Krish) @tellkrish.bsky.social · 13/09/2023
Hi Bluesky. I recently started my lab at the Surgery Branch, National Cancer Institute. We study T cell Immunology in human cancer patients with the goal of developing cell therapies. Pls share this, join us if you're interested! We are looking for postdocs! ccr.cancer.gov/staff-direct...
1110